What is MDAI?
MDAI (5,6-methylenedioxy-2-aminoindane) is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin releasing agent (SSRA) in vitro and produces entactogen effects in humans. Buy MDAI online. https://psychonautwiki.org/wiki/2-Aminoindane
It is a legal stimulant and club drug. Chemically it is 5,6-Methylenedioxy-2-aminoindane. It is a granular, brownish powder which is snorted or bombed. https://levelupchem.com/
The effects which occur during the offset of a stimulant experience generally feel negative and uncomfortable in comparison to the effects which occurred during its peak. This is often referred to as a “comedown” and occurs because of neurotransmitter depletion. Its effects commonly include:
It can take an hour to work but its effects. It gives a sense of euphoria and well-being. Music is enhanced and you may talk incessantly. You may also be more easily aroused sexually. MDAI also suppresses the appetite very effectively. https://en.wikipedia.org/wiki/2-Aminoindane
Stimulants like it can give a powerful rush of sensations. Reports suggest its stimulant qualities such as getting the heart racing are much less than many other stimulants like ecstasy. Its effects are more empathetic. But it is a strong drug so you may feel distressed by its powerful effects if you are a relative novice to stimulants of this kind. The high last about six hours but the main peak is perhaps two hours. https://levelupchem.com/index.php/product/ephedrine/
The drug also has psychedelic effects or hallucinations. It can make your body temperature rise. You may develop paranoia or experience panic attacks. https://levelupchem.com/index.php/product/trenbolone-enanthate/
The visual effects of it only occur at higher doses and are reported to be only subtly psychedelic in nature. These generally include:
Visual acuity enhancement
It currently appears that serotonergic aminoindane representatives such as MDAI, MMAI or 5-IAI play a relatively minor role on the novel psychoactive substance market for recreational drugs. Buy MDAI online. https://levelupchem.com/index.php/product/amphetamine/
MDAI is a new psychoactive substance (NPS) that
has structural similarities to MDA and MDMA and shares some of
their behavioural properties1,2,7.
Chemical name: 5,6 methylenedioxy-2-aminoindane.
Street names: Sparkle, Mindy, MDAI Gold.
Some common keywords:
MDAI, abuse potential, locomotor activity, drug discrimination, place conditioning, rat, mouse
Methylenedioxy-2-aminoindane (MDAI) is a drug originally synthesised by the American pharmacologist and medicinal chemist, David E. Nichols during the 1990s at Purdue University. Ordinarily, it appears as a tan-coloured, crystalline powder. https://levelupchem.com/index.php/product/cocaine/
It is derived from the drug -3, 4-methylenedioxyamphetamine (MDA) – a single structural alteration is the only difference between the two drugs. However, due to this structural change occurring in the region responsible for typical amphetamine-like responses, significant pharmacological differences are seen when comparing MDAI with MDA.
Appearance of MDAI:
It is sold in powder, capsule or pellet form, and has
also been an ingredient in branded products. There have been three versions of MDAI available: a white powder, a tan powder and lastly MDAI Gold, which is a fluffy, slightly crystalline powder with a more ‘sparkly’ look. https://levelupchem.com/index.php/product/piperonyl-methyl-ketone/
5,6-Methylenedioxy-2-aminoindane (MDAI) has become a common substitute for (±)-3,4-methylenedioxymethamphetamine (MDMA) in Ecstasy.
It is known to produce MDMA-like discriminative stimulus effects, but it is not known whether MDAI has psychostimulant or hallucinogen-like effects.
It was tested for locomotor stimulant effects in mice and subsequently for discriminative stimulus effects in rats trained to discriminate cocaine (10 mg/kg, i.p.), methamphetamine (1 mg/kg, i.p.), ±MDMA (1.5 mg/kg, i.p.), or (−)-2,5-dimethoxy-4-methylamphetamine hydrochloride (DOM) (0.5 mg/kg, i.p.) from saline.
The ability of MDAI to produce conditioned place preference was also tested in mice. MDAI (3 to 30 mg/kg) depressed locomotor activity from 10 to 60 min. A rebound stimulant effect was observed at 1 to 3.5 hr following 30 mg/kg. Lethality occurred in 8/8 mice following 100 mg/kg MDAI.
Similarly, MDMA depressed locomotor activity immediately following administration of 0.25 mg/kg and stimulant effects were observed 50–70 min following administration of 0.5 and 1 mg/kg.
It fully substituted for the discriminative stimulus effects of MDMA (2.5 mg/kg), DOM (5 mg/kg) and cocaine (7.5 mg/kg), but produced only 73% methamphetamine-appropriate responding at a dose that suppressed responding (7.5 mg/kg). MDAI produced tremors at 10 mg/kg in one methamphetamine-trained rat.
MDAI produced conditioned place preference from 0.3 to 10 mg/kg. The effects of MDAI on locomotor activity and drug discrimination were similar to those produced by MDMA, having both psychostimulant- and hallucinogen-like effects, so MDAI may have similar abuse potential as MDMA.
It has been shown to strongly stimulate the release of the neurotransmitter serotonin in research models and can therefore be described as being a ‘selective serotonin releasing agent’ (SSRA). Serotonin (or 5-HT), is mainly found in the intestines and central nervous system where it is involved in the regulation of processes such as: intestinal movement, sleep, mood, appetite, memory and learning.
The extent to which MDAI stimulates serotonin release is comparable to that seen with MDA but less than is seen with 3, 4-methylenedioxy-N-methylamphetamine (MDMA).
In humans, MDAI has been shown to produce heightened feelings of empathy, love and emotional closeness with others. Drugs producing these effects are known as entactogens (or empathogens) and in addition to MDAI, include MDMA and related ‘MDxx’ drugs.
In contrast to many similar drugs, MDAI has been found to be largely non-stimulating and has so far proven to cause neurotoxicity when taken by without any other drugs. Reliable data concerning toxic effects on the heart (a known problem with many amphetamine and amphetamine-like drugs) has yet to be gathered for MDAI.
It has also been found to inhibit the reuptake (movement back into cells) of serotonin as well as (to a lesser degree) the neurotransmitters dopamine (involved in regulating reward-seeking behaviour) and norepinephrine (or noradrenaline –a primary stress hormone).
Subjective user reports have indicated that mild pharmacological effects are seen at doses between 150mg-250mg, with significant effects above this. However, factors such as a user’s weight, previous usage and metabolism are just some variables that would determine an individual’s response to MDAI.
Adulteration with other drugs (including the now illegal drug mephedrone), has been found in samples being sold as MDAI and this could also significantly alter the pharmacological and toxic effects produced.